Scarica l'app Stockscreener
0.8582
2.04%
-0.0179
Prelude Therapeutics Inc Borsa (PRLD) Ultime notizie
Baker Bros. Advisors LP Increases Stake in Prelude Therapeutics Inc. - GuruFocus
Two Sigma Investments LP Purchases 174,906 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares Acquired by Millennium Management LLC - Defense World
20,572 Shares in Prelude Therapeutics Incorporated (NASDAQ:PRLD) Purchased by BNP Paribas Financial Markets - Defense World
Two Sigma Advisers LP Raises Holdings in Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Prelude Therapeutics describes new SMARCA2 and SMARCA4 degradation inducers - BioWorld MedTech
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares Sold by Northern Trust Corp - Defense World
Prelude Therapeutics to Present at Major Healthcare Conferences in June 2025 - MyChesCo
Prelude Therapeutics to Participate in Upcoming Healthcare Confe - GuruFocus
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences | PRLD Stock News - GuruFocus
Precision Oncology Pioneer Prelude Therapeutics Sets Stage for Major June Healthcare Conference Updates - Stock Titan
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences - Yahoo Finance
Central Nervous System Tumors Pipeline Appears Robust With 13+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Prelude Therapeutics’ SWOT analysis: clinical progress buoys stock amid challenges - Investing.com India
Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal - insights.citeline.com
AI-powered drug development startup Pathos AI closes $365M investment - SiliconANGLE
Pathos AI secures $365M series D to fund trial of Novo Nordisk solid tumor drug - Fierce Biotech
Palvella Therapeutics to Announce Q1 2025 Financial Results and Host Investor Call - MyChesCo
Mineralys Therapeutics to Present at Bank of America Health Care Conference - MyChesCo
Prelude Therapeutics Reports Q1 2025 Financial Results and Progress on Clinical Programs - MyChesCo
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares Sold by Price T Rowe Associates Inc. MD - The AM Reporter
What is HC Wainwright’s Estimate for PRLD Q2 Earnings? - Defense World
SEED Therapeutics Unveils Groundbreaking Advances in Cancer Research at AACR 2025 - MyChesCo
Q1 Earnings Forecast for PRLD Issued By HC Wainwright - Defense World
Prelude Therapeutics Reports Q1 2025 Financial Results - TipRanks
JPMorgan Chase & Co. Purchases 55,183 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Prelude Therapeutics (NASDAQ:PRLD) Given Buy Rating at HC Wainwright - Defense World
Prelude Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Prelude Therapeutics (PRLD) Rating Reiterated with $5 Target by HC Wainwright | PRLD Stock News - GuruFocus
Prelude Therapeutics to Host Fireside Chat at Citizens Life Sciences Conference 2025 - MyChesCo
Prelude Therapeutics (PRLD) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Prelude Therapeutics Inc expected to post a loss of 47 cents a shareEarnings Preview - TradingView
Renaissance Technologies LLC Increases Holdings in Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Prelude Therapeutics to Participate in Citizens Life Sciences Conference - Bluefield Daily Telegraph
Aclaris Therapeutics Welcomes Dr. Jesse Hall as Chief Medical Officer - MyChesCo
JMP Securities Reaffirms Market Outperform Rating for Prelude Therapeutics (NASDAQ:PRLD) - Defense World
Prelude Therapeutics Unveils Promising Preclinical Data on Novel Cancer Therapies - MSN
JMP maintains $4 target on Prelude Therapeutics stock By Investing.com - Investing.com Canada
Incyte to Showcase Latest Oncology Advancements at 2025 ASCO Meeting - MyChesCo
Prelude Announces Presentations at 2025 AACR Annual Meeting | PR - GuruFocus
Prelude Therapeutics Presents Preclinical Data on First-in-Class SMARCA2 and Selective KAT6A Degraders at AACR Annual Meeting - Nasdaq
Prelude Announces Presentations at 2025 AACR Annual Meeting - Yahoo Finance
Aclaris Therapeutics Secures FDA Clearance for ATI-052 Clinical Trial - MyChesCo
Century Therapeutics Hosts Live Fireside Chat on Groundbreaking Cell Therapy Advances - MyChesCo
HC Wainwright Issues Positive Forecast for PRLD Earnings - Defense World
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should Know - MSN
PRLD stock touches 52-week low at $0.61 amid market challenges - Investing.com
Charles Schwab Investment Management Inc. Sells 16,049 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Context Therapeutics Announces Participation in Key Investor Conferences - MyChesCo
Palvella Therapeutics Reports 2024 Financial Results and Advances Rare Disease Pipeline - MyChesCo
Prelude Therapeutics reports preclinical profile of first-in-human SMARCA2 degrader - BioWorld MedTech
Prelude Therapeutics Founder Acquires 28% More Stock - Yahoo
1.14%
0.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):